Please assess the completion status of the following clinical trial:

Trial Title: Neurobiological Bases of Placebo Response in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets diagnostic criteria for Major Depressive Disorder~* Written informed consent~* Men or women aged 18-60 years old~* A score of 18 or greater on the HAMD-28~* Patient must continue to meet criteria for current MDD at baseline. Patients must have Clinical Global Impression Improvement (CGI) scores ≥ 3 (i.e. minimally improved or less) from the screen to the baseline visit~* Agreeing to, and eligible for all procedures (only patients 18-45 will be eligible for MR-PET study)~Exclusion Criteria:~* Pregnant women or women of child bearing potential not using a medically accepted means of contraception~* Patients who are a serious suicide or homicide risk~* Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease, uncontrolled seizure disorder~* The following DSM-IV diagnoses: a) organic mental disorders b) substance use disorders, including alcohol, active within the last year; c) schizophrenia; d) delusional disorder; e) psychotic disorders not elsewhere classified; f) bipolar disorder; g) acute bereavement; h) borderline or antisocial personality disorder i) current primary diagnoses of panic disorder, social phobia, GAD, or OCD (disorders that present as chief complaint and/or have their onset preceding the onset of MDD), l) Patients with mood congruent or mood incongruent psychotic features~* Currently taking any of the following exclusionary medications: antipsychotics, anticonvulsants, mood stabilizers, stimulants, antidepressants, potential antidepressant augmenting agents (e.g., T3, SAMe, St. John's Wort, lithium, buspirone, Omega 3 fatty acids). If it is determined that it is safe to discontinue a medication, the patient will be required to wait a period equivalent to at least 5 half lives of the drug before the screening~* Patients who have taken an investigational psychotropic drug within the last year~* Patients who have not responded to one or more antidepressant trials of adequate doses (e.g., fluoxetine 40 mg/day or higher) and duration (e.g., for six weeks or more) over the past five years, as defined by the MGH-ATRQ~* History of inadequate response or poor tolerability to citalopram or escitalopram~* Any concomitant form of psychotherapy (depression-focused)~* Receiving or have received during the index episode Vagal nerve stimulation, ECT or rTMS, or other somatic antidepressant treatments~* Any reason not listed, determined by the site PI or study clinician, constituting good clinical practice and making participation in the study hazardous~* Contraindications to fMRI scanning and MR-PET scanning (including presence of a cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia)~* MR-PET-specific exclusion criteria: Patients who are younger than 18 or older than 45 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): After a screening visit, the patient will undergo a baseline assessment and will be randomized to escitalopram 10mg or placebo.
- Escitalopram 10mg (Type: EXPERIMENTAL): After a screening visit, the patient will undergo a baseline assessment and will be randomized to escitalopram 10mg or placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).